Zurück geht es hier Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.
27.05.2025 09:43:24

EQS-Adhoc: Pentixapharm Holding AG: Pentixapharm outlines new clinical development strategy

EQS-Ad-hoc: Pentixapharm Holding AG / Key word(s): Study
Pentixapharm Holding AG: Pentixapharm outlines new clinical development strategy

27-May-2025 / 09:43 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.


 

Ad hoc announcement pursuant to Art. 17 MAR / Section 15 WpHG

 

Pentixapharm outlines new clinical development strategy

Clinical pipeline to be refocused on theranostic precision oncology opportunities to enhance value proposition of lead assets

The PTF301 diagnostic trial in Marginal Zone Lymphoma (MZL) will be discontinued.

New CXCR4 trials in hematologic malignancies and Bladder Cancer in preparation

Berlin, Germany, May 27, 2025 – Pentixapharm AG, the operating subsidiary of Pentixapharm Holding AG, a clinical-stage biopharmaceutical company focused on radiopharmaceuticals, today outlined a new clinical development strategy for its CXCR4 therapeutic and diagnostic oncology programs, following a management review led by recently appointed CEO and CMO Dr. Dirk Pleimes and CBO Henner Kollenberg.

The management of Pentixapharm strongly believes the new clinical strategy for the CXCR4 programs will increase the value proposition of the CXCR4 targeting assets. The decision was approved by Pentixapharm’s Supervisory Board at a meeting held earlier today.

Pentixapharm will refocus its clinical development efforts and resource into a theranostic basket program that will evaluate the efficacy of the Company’s CXCR4-targeted therapeutic approach across various hematological malignancies that overexpress the CXCR4 chemokine receptor. An additional clinical Phase I/II in trial in Bladder Cancer is currently in preparation. Pentixapharm will provide further detail on these new trials in due course.

Following implementation of the new clinical development strategy, the Company’s current PTT101 therapeutic trial in the Central Nervous System (CNS) Lymphoma will be integrated into the theranostic basket program. The PTF301 diagnostic trial in Marginal Zone Lymphoma (MZL) will be discontinued due to low patient recruitment.

Outside oncology, Pentixapharm continues its commitment to advance [68Ga]Ga-PentixaFor as a first-in-class, non-invasive diagnostic solution for primary aldosteronism (PA) and explores the best route towards realizing the value for the registrational clinical development and commercialization phase. 

“This strategic decision will help us to contribute significantly to the value of our theranostic CXCR4 pipeline. We are deeply grateful to the patients, investigators, and teams who have supported our clinical progress. This work has provided us with an excellent basis for the review and re-design of our clinical pipeline. The basket trial program is designed to systematically identify indications where our CXCR4 theranostic platform can deliver the greatest clinical benefit and value to patients with hematologic malignancies,” said Dr. Dirk Pleimes, CEO of Pentixapharm. “We are looking forward to presenting the new trials in more detail at upcoming scientific and investor conferences.”

“The review of the clinical pipeline will enable us to focus on larger indications with a higher market potential,” added Henner Kollenberg, CBO of Pentixapharm. “While the previous trials delivered supportive data on our compounds and underlined the strengths of our CXCR4 portfolio, the business case for the orphan drug diagnostic and long recruitment times for both programs represented a significant challenge for their future commercialization. We now look forward to progressing with a renewed focus on improving treatment options and outcomes for thousands of patients with aggressive forms of leukemias, myeloma and lymphoma and more broadly in high-value opportunities from the use of radiopharmaceuticals in precision oncology.”

 

Forward-looking statements

This ad hoc announcement contains forward-looking statements that are based on the current expectations, forecasts and assumptions of Pentixapharm Holding AG. Forward-looking statements are inherently subject to risks and uncertainties because they depend on future events and developments that cannot be fully controlled. Therefore, actual results may differ materially from the expectations expressed herein. Pentixapharm Holding AG assumes no obligation to update forward-looking statements or to adapt them to changes in circumstances, unless required by law.

 

About Pentixapharm

Pentixapharm is a clinical-stage biotech company discovering and developing novel targeted radiopharmaceuticals with offices in Berlin and Würzburg, Germany. It is committed to developing first-in-class radiopharmaceuticals with strong differentiation and commercialization potential across high-need diagnostic and therapeutic areas. Its pipeline comprises CXCR4-targeted peptides in clinical development and a portfolio of early-stage radionuclide-antibody conjugates, aimed at using precision oncology to treat hematologic malignancies and solid tumors.

 

For more information, please contact:

Pentixapharm Holding AG
Investor Relations
ir@pentixapharm.com
Tel. +49 30 94892600
www.pentixapharm.com

 



End of Inside Information

27-May-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Pentixapharm Holding AG
Robert-Rössle-Straße 10
13125 Berlin
Germany
E-mail: info@pentixapharm.com
Internet: https://www.pentixapharm.com/
ISIN: DE000A40AEG0
WKN: A40AEG
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 2145888

 
End of Announcement EQS News Service

2145888  27-May-2025 CET/CEST

Analysen zu Pentixapharm Holding AG Unitary

  • Alle
  • Kaufen
  • Hold
  • Verkaufen
  • ?
Zu diesem Datensatz liegen uns leider keine Daten vor.
Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen

Buffett geht, Trump regiert – Zerreissprobe für die Wall Street? mit Tim Schäfer | BX Swiss TV

Was passiert bei Berkshire Hathaway nach Buffetts Rückzug? Wie wirkt sich die aktuelle US-Zollpolitik auf Stimmung und Märkte aus? Und welche Value-Aktien sieht Tim Schäfer @TimSchaeferMedia aktuell als kaufenswert? In diesem Gespräch gibt der bekannte New-York-Korrespondent Einblicke direkt von der Invest.

🔍 Themen im Video:

🔹 Warren Buffetts Rückzug & die Zukunft von Berkshire Hathaway
🔹 Cash-Berge & Dividendenstrategien bei grossen Holdings
🔹 Auswirkungen der US-Zollpolitik auf Bevölkerung & Börsen
🔹 Stimmung in den USA: Altersvorsorge & politische Unsicherheit
🔹 Value Investing in Krisenzeiten: Was Tim gerade gekauft hat
🔹 UnitedHealth, Kostendruck & Chancen bei Rücksetzern
🔹 Erste Eindrücke von der Invest 2025 in Stuttgart
🔹 Finanzbildung, Auswandern & junge Anleger
🔹 Persönliche Einblicke: Tim Schäfers Reisepläne & Lebensstil

👉🏽 Jetzt auch auf BXplus anmelden und von exklusiven Inhalten rund um Investment & Trading profitieren!

Buffett geht, Trump regiert – Zerreissprobe für die Wall Street? mit Tim Schäfer | BX Swiss TV

Mini-Futures auf SMI

Typ Stop-Loss Hebel Symbol
Short 12’646.85 18.74 B0LSNU
Short 12’879.20 13.50 SS4MTU
Short 13’348.46 8.81 BDGS0U
SMI-Kurs: 12’202.97 02.06.2025 16:44:32
Long 11’723.36 19.68 BQUSIU
Long 11’426.71 13.27 BH2SIU
Long 10’978.59 8.88 B38SLU
Die Produktdokumentation, d.h. der Prospekt und das Basisinformationsblatt (BIB), sowie Informationen zu Chancen und Risiken, finden Sie unter: https://keyinvest-ch.ubs.com

finanzen.net News

Datum Titel
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
{{ARTIKEL.NEWS.BODY.TITEL}}